BERLIN -- Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression with the addition of radioligand therapy to hormonal treatment, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback